Accessability Links
Cookies on our website
By continuing to use this website we will assume you are happy to receive cookies as outlined in our cookie policy
Accept Policy

Preclinical/Phase I

Strategy & delivery of early-phase clinical development services

Preclinical/Phase 1 specialise in the strategy and delivery of early-phase clinical development services. This enables us to provide informed, timely decisions for our clients.

Our Development Solutions teams have expertise in early phase clinical research, bioanalytics, PK-PD modelling and simulation as well as the full range of supporting services. In everything we do we incorporate scientific excellence and product development strategy.

Our experts are multi-disciplinary and have the experience to address even the most demanding of drug development challenges with an uncompromising focus on completing projects on time, within budget and to a standard that will always shine under even the most critical scrutiny.


In this area our key services include:

• Product development consulting
• Bioanalytical
• PK/PD Modelling and simulation
• Population PK
• Data Analysis (TK, PK, PK/PD)
• Regulatory affairs strategy / submission
• Protocol design 
• Medical Writing
• Quality Control/Assurance
• Pharmacodynamic Models
• Clinical studies including:
• Food effect studies
• Dosage Regimen assessments
• Diabetic Clamp studies
• QTc studies
• First in man, dose escalation, PK/PD
• Multiple dose studies
• Drug interaction studies
• Bioavailability, bioequivilence
• Phase I patient studies
• Special population studies
• Patient studies
• Special population studies
• Proof of concept studies


If you'd like to learn more about our current vacancies in this area please click here.

Services
ICON News
Clinical Research Management Jobs ICON Careers are a specialist Recruitment Agency, currently recruiting to fill vacancies across the ... Read more
ICON Awarded Best CRO at World Vaccines Congress 2014 ICON plc, is pleased to announce that it has been named Best Clinical Research Organisation i... Read more
ICON Reports Fourth Quarter 2013 Revenue of $345 million, up 15% year on year and EPS of 53c, up 56% ICON Reports Fourth Quarter 2013 Revenue of $345 million, up 15% year on year and EPS of 53c, up 5... Read more
 

Back to Top